SNDX Syndax Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SNDX

Price (delayed)

$22.05

Market cap

$1.87B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.98

Enterprise value

$1.58B

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin-MLL binding interaction, axatilimab, ...

Highlights
SNDX's equity has soared by 54% QoQ and by 19% YoY
SNDX's debt is up by 41% YoY but it is down by 13% from the previous quarter
The quick ratio has contracted by 41% YoY but it has grown by 3.2% from the previous quarter
The net income has contracted by 40% YoY and by 19% from the previous quarter
The EPS has declined by 21% year-on-year and by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.syndax.com
Peers: OMER OMGA

Key stats

What are the main financial stats of SNDX
Market
Shares outstanding
84.97M
Market cap
$1.87B
Enterprise value
$1.58B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.77
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$209.15M
EBITDA
-$208.4M
Free cash flow
-$160.6M
Per share
EPS
-$2.98
Free cash flow per share
-$2.28
Book value per share
$7.96
Revenue per share
$0
TBVPS
$8.71
Balance sheet
Total assets
$612.88M
Total liabilities
$58.68M
Debt
$1.64M
Equity
$554.2M
Working capital
$522.78M
Liquidity
Debt to equity
0
Current ratio
10
Quick ratio
9.95
Net debt/EBITDA
1.41
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-44%
Return on equity
-47.9%
Return on invested capital
-69%
Return on capital employed
-37.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SNDX stock price

How has the Syndax Pharmaceuticals stock price performed over time
Intraday
0.87%
1 week
4.7%
1 month
-7.31%
1 year
8.19%
YTD
2.04%
QTD
-7.35%

Financial performance

How have Syndax Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$229.95M
Net income
-$209.36M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 52% YoY and by 18% from the previous quarter
The net income has contracted by 40% YoY and by 19% from the previous quarter

Growth

What is Syndax Pharmaceuticals's growth rate over time

Valuation

What is Syndax Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.77
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 21% year-on-year and by 16% since the previous quarter
SNDX's equity has soared by 54% QoQ and by 19% YoY
SNDX's price to book (P/B) is 31% lower than its 5-year quarterly average of 4.0 and 11% lower than its last 4 quarters average of 3.1

Efficiency

How efficient is Syndax Pharmaceuticals business performance
The return on invested capital has declined by 37% year-on-year and by 32% since the previous quarter
The company's return on equity fell by 24% YoY and by 13% QoQ
Syndax Pharmaceuticals's return on assets has decreased by 24% YoY and by 12% QoQ

Dividends

What is SNDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SNDX.

Financial health

How did Syndax Pharmaceuticals financials performed over time
The total liabilities has surged by 97% year-on-year and by 47% since the previous quarter
The total assets has soared by 54% from the previous quarter and by 23% YoY
SNDX's debt is 100% less than its equity
The debt to equity has dropped by 100% since the previous quarter
SNDX's equity has soared by 54% QoQ and by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.